<strong>CEVEC</strong> is a biotechnology company specialized in the production of biopharmaceuticals using its proprietary CAP-Technology, a unique human suspension cell-based production platform. <strong>CAP-GT</strong> cell lines enable scalable viral gene therapy vector production with easy handling and competitive production costs when compared to adherent cell culture systems. <img class="wp-image-68323 alignright" src="https://www.goingpublic.de/wp-content/uploads/2017/09/Cevec_Labor_1.jpg" alt="" width="155" height="138" />In addition, the Company has developed a helper-free AAV (adeno-associated virus) packaging cell line for scalable stable gene therapy vector production independent of transient transfection or helper virus. <strong>CAP-Go</strong> enables the production of recombinant proteins previously out of reach that are notoriously difficult to express in conventional cell lines including blood coagulation factors, C1-Inhibitor and others. <h3>Overview:</h3> <table border="0" width="100%" cellspacing="0" cellpadding="0"><colgroup> <col width="50%" /> <col width="50%" /></colgroup> <tbody> <tr valign="top"> <td><strong>Field of Activity </strong></td> <td>Development and licensing of cell-based production platforms for biopharmaceuticals</td> </tr> <tr valign="top"> <td><strong>Ownership Structure and Financing</strong></td> <td>Privately owned; investors are Peppermint VenturePartners, Creathor Venture, NRW.Bank, KfW Bank, G.A.T. Holding, Investtodate GmbH and several private persons.</td> </tr> <tr valign="top"> <td><strong>Partners</strong></td> <td>Selected license partners: Beckman Research Institute, BioLamina AB, Biotest AG, CellGenix GmbH, CSL Limited, Généthon, medac, PlasmidFactory GmbH & Co. KG and Provecs Medical GmbH CDMO partners: Paragon Bioservices Inc. and GenIbet Biopharmaceuticals</td> </tr> <tr valign="top"> <td><strong>Technology and Unique Selling Point </strong></td> <td>CEVEC´s human suspension cell-based CAP technology provides fully scalable, clinical-grade good manufacturing practice (GMP) compatible solutions for the production of viral gene therapy vectors and recombinant glycoproteins. The CAP-GT platform includes a helperfree AAV packaging cell line for stable vector production and RCA-free production of adenoviral vectors for gene therapy applications. The CAP-Go system provides outstanding pharmacokinetic profi les and characteristics in terms of authentic and tailor-made glycosylation capabilities as well as high yield production of complex proteins.</td> </tr> <tr valign="top"> <td><strong>Products / Services</strong></td> <td>Cell line and process development and technology licensing for the pro duction of tailor-made recombinant glycoproteins and gene therapy vectors.</td> </tr> <tr valign="top"> <td><strong>Membership in networks / associations </strong></td> <td>BioRiver, Bio Cologne, Bio Deutschland, BIOCOM, Dechema, VCI</td> </tr> <tr> <td><strong>Date of Incorporation / </strong><strong>Number of Employees</strong></td> <td>2003 / 30 employees</td> </tr> </tbody> </table> <h3></h3> <hr /> <h3><img class="alignnone wp-image-68324 size-full" src="https://www.goingpublic.de/wp-content/uploads/2017/09/CEVEC_GettyImages-6758226821-1.jpg" alt="" width="279" height="208" /></h3> <h3>Contact:</h3> <table border="0" width="100%" cellspacing="0" cellpadding="0"><colgroup> <col width="50%" /> <col width="50%" /></colgroup> <tbody> <tr> <td><strong>Telephone</strong></td> <td>+49 221 460 208-00</td> </tr> <tr> <td><strong>Telefax</strong></td> <td>+49 221 460 208-01</td> </tr> <tr> <td><strong>E-Mail</strong></td> <td><a href="info@cevec.com">info@cevec.com</a></td> </tr> </tbody> </table> <h3>Address:<strong> </strong></h3> CEVEC Pharmaceuticals GmbH Gottfried-Hagen-Straße 60-62 51105 Cologne Germany <h3>Web-Address:</h3> <a href="http://www.cevec.com" target="_blank" rel="noopener">www.cevec.com</a> <img class="alignnone wp-image-74436 size-full" src="https://www.goingpublic.de/wp-content/uploads/2018/09/CEVEC_Steckbrief_Bild_3_unten_rechts-2.jpg" alt="" width="280" height="239" /> <hr />
Jetzt LifeSciencesUpdate abonnieren und kostenloses GoingPublic-Ticket für die LABVOLUTION 21. – 23. Mai 2019 in Hannover gewinnen!
